Table 1 |
|||
|
Clinical features of the participants who contributed plasma |
|||
|
Characteristics |
RA |
OA |
HC |
|
|
|||
|
Number of participants |
30 |
30 |
30 |
|
Sex, male/female |
8/22 |
7/23 |
13/17 |
|
Age, mean (range) |
60.1 (22 to 77) |
75.1 (65 to 89) |
46.5 (32 to 62) |
|
Disease duration (y), mean (range) |
10.4 (0.3 to 32) |
NA |
NA |
|
Positive anti-CCP antibody, n (%) |
10 (90.9%)† |
NA |
NA |
|
ESR (mm), mean (range) |
37.2 (4 to 116) |
NA |
NA |
|
CRP (mg/dl), mean (range) |
2.1 (0 to 9.6) |
NA |
NA |
|
MMP3 (ng/ml), mean (range) |
290.1 (32.4 to 800) |
NA |
NA |
|
DAS28, mean (range) |
4.4 (1.7 to 7.1) |
NA |
NA |
|
SJC, mean (range) |
4.3 (0 to 13) |
NA |
NA |
|
TJC, mean (range) |
4.5 (0 to 27) |
NA |
NA |
|
VAS |
42.3 (0 to 95) |
NA |
NA |
|
Steinbrocker Stage, n |
I: 4, II: 3, III: 6, IV: 17 |
NA |
NA |
|
Steinbrocker Class, n |
I: 1, II: 24, III: 5, IV: 0 |
NA |
NA |
|
Kellgren/Lawrence grade, n |
NA |
I: 0, II: 0, III: 9, IV: 21 |
NA |
|
Medication, n (%) |
|||
|
Prednisolone |
21 (70%) |
NA |
NA |
|
Methotrexate |
18 (60%) |
NA |
NA |
|
Infliximab |
8 (27%) |
NA |
NA |
|
Eternercept |
2 (6.7%) |
NA |
NA |
|
Tocilizumab |
2 (6.7%) |
NA |
NA |
|
Tacrolimus |
2 (6.7%) |
NA |
NA |
|
Salazosulfapyridine |
6 (20%) |
NA |
NA |
|
Bucillamine |
5 (17%) |
NA |
NA |
|
Mizoribine |
0 (0%) |
NA |
NA |
|
Gold |
1 (3.3%) |
NA |
NA |
|
|
|||
|
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; HC, healthy control; MMP-3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale of general health; † anti-CCP antibodies of 10 patients were positive among 11 patients examined. |
|||
|
Murata et al. Arthritis Research & Therapy 2010 12:R86 doi:10.1186/ar3013 |
|||
